Spurned J&J vice chair jumps ship for Avon; Roche may boost Illumina bid again;

 @FierceMedDev: FDA approves Lilly's brain plaque diagnostic tool. Item | Follow @FierceMedDev

> Johnson & Johnson ($JNJ) Vice Chairman Sherilyn S. McCoy will leave the company to become CEO of Avon Products, two months after being passed over for J&J's top spot in favor of Alex Gorsky, The Wall Street Journal reports. Blog

> BioMarCare Technologies plans to use a $900,000 grant from the Israel-United States Binational Industrial Research and Development Foundation to develop biomarkers that help predict the response to certain drugs for colon cancer patients, Globes reports. Story

> On-Q-ity is generating promising data for OnQChip, a technology designed to detect circulating tumor cells in the blood of cancer patients. The company presented details at the recent AACR meeting in Chicago. Release

> California's Bioness has begun a clinical study to evaluate the safety and effectiveness of its StimRouter neuromodulation system to treat chronic peripheral nerve pain. Release

> Mount Sinai School of Medicine researchers have developed a way to derive enough DNA information from non-DNA sources--such as RNA--to clearly identify patients whose biological data is stored in massive research repositories. Release

And Finally... Roche ($RHHBY) has said it is willing to consider "additional value" in its ongoing bid for Illumina ($ILMN), suggesting that it may raise its offer for the company again, Reuters reports. Story

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.